DOYLESTOWN, PA — Aprea Therapeutics, Inc. (NASDAQ: APRE) will present updated interim results from its Phase 1 trial of WEE1 inhibitor APR-1051 in November, providing a new clinical readout from the company’s experimental treatment for patients with advanced solid tumors.
The data from the ongoing ACESOT-1051 study have been accepted for an oral plenary presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, scheduled for Nov. 18-20 in Barcelona, Spain.
APR-1051 is being evaluated in a first-in-human Phase 1 study involving patients with advanced solid tumors. Aprea is a clinical-stage precision oncology company developing targeted therapies for biomarker-defined cancers.
Timothy A. Yap of the University of Texas MD Anderson Cancer Center will present the interim findings Nov. 20 from 3 p.m. to 3:10 p.m. CET at the CCIB in Barcelona. Yap is an investigator in the ACESOT-1051 study and works in MD Anderson’s Department of Investigational Cancer Therapeutics, Division of Cancer Medicine.
“We look forward to presenting an update from our ongoing Phase 1 ACESOT-1051 trial at the EORTC-NCI-AACR Symposium and sharing these data with the international oncology community,” Aprea President and Chief Executive Officer Oren Gilad stated.
The presentation is titled “Interim results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051).”
Additional information about the ACESOT-1051 trial is available through ClinicalTrials.gov under identifier NCT06260514.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.